Comparison of tumor-agnostic and tumor-specific clinical oncology trial designs - supplementary material

Supplementary Table 1: Tumor-Specific Trial Search Strategy Supplementary Table 2: Tumor-Agnostic Trial Search Strategy Exhibit 3: Tumor-agnostic trial characteristics Supplementary Table 4: Tumor-agnostic cohort characteristics Supplementary Table 5: Progression-free survival (PFS) and overall survival (OS) estimates from tumor-agnostic trials. Supplementary Table 6: Tumor-specific trial characteristics Supplementary Table 7: Tumor-specific cohort characteristics Supplementary Table 8. Progression-free survival (PFS) and overall survival (OS) estimates from tumor-specific trials. Supplementary Figure 1: Meta-analysis of BRAF inhibitors by trial type. Supplementary Figure 2: Meta-analysis of BRAF/MEK inhibitors by trial type.